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ECONOMIC EVALUATION OF ORAL THERAPIES FOR
PULMONARY ARTERIAL HYPERTENSION
Harnett J1,Van Engen A2, Schoeman O2
1Pﬁzer Inc, New York, NY, USA, 2Quintiles Consulting, Hoofddorp,The
Netherlands
OBJECTIVES: The objective of this study was to create an eco-
nomic model for evaluation of two oral therapies for pulmonary
arterial hypertension (PAH) in the US. METHODS: Using a
Markov model, expected outcomes and costs for PAH patients
treated with either RevatioTM (sildenaﬁl citrate) or TracleerTM
(bosentan) were evaluated over a 1 year period. The health states
in the model were based on the World Health Organization func-
tional class I to IV and death. Transition probabilities and utili-
ties were based on the results of the SUPER-1 clinical trial for
RevatioTM. Treatment effect was estimated using relative risk of
improvement in 6-minute walk tests for sildenaﬁl and bosentan
based on pivotal clinical trials. Costs were derived from average
wholesaler price and Medicare reimbursement data. Sensitivity
analyses were performed in order to test the strength of the con-
clusions of the analysis over a range of structural assumptions,
probability estimates and value judgments. RESULTS: Sildenaﬁl
therapy was associated with signiﬁcant cost savings ($3.0 million
per 100 patients per year) in comparison with bosentan. Life-
year and QALY differences between sildenaﬁl and bosentan were
found to be negligible. CONCLUSIONS: The results show that
sildenaﬁl is more cost-effective than bosentan mainly due to the
large difference in medication costs (in favor of sildenaﬁl).
PCV19
ONE-YEAR COSTS FOR ACUTE CORONARY SYNDROME IN
PATIENTS WITH AND WITHOUT REVASCULARIZATION
DURING THE INITIAL HOSPITALIZATION
Sidney S1, Sorel M1, Quesenberry Jr CP1, McCollam PL2
1Kaiser Permanente Medical Care Program, Oakland, CA, USA, 2Eli
Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Revascularization procedures are often carried
out during hospitalizations for acute coronary syndrome (ACS).
Our objectives are to estimate the costs during the ﬁrst year of
follow-up after initial (index) hospitalization for ACS stratiﬁed
by whether or not revascularization took place at this hospital-
ization. METHODS: This consisted of Kaiser Permanente
Medical Care Program Nothern California patients age >40
years, and hospitalized with ACS during January 1, 1999 to
December 31, 2000, and without ACS hospitalization during 6
months prior. Costs expressed are those incurred by the health
plan. RESULTS: A total of 14,852 patients met inclusion crite-
ria. Mean age was 67.2 years; 63.9% were male. The distribu-
tion of revascularization during index hospitalization was 2457
CABG (16.5%), 3257 PCI (21.9%), and 9138 no procedure
(61.5%). Index total hospitalization costs were: CABG ($34,307
+ 26,515), PCI ($14,863 + $11,665), no procedure ($11,059 +
16,497). One-year follow-up costs were highest for no procedure
[$17,669 + 32,510 ($7,781 median)], intermediate for CABG
[$12,763 + 22,676 ($5,670)] lowest for PCI [$12,297 + 22,197
($4,336)]. Percent of total costs by type of resource used (clinic,
hospital, pharmacy, respectively) were for CABG 36.5%, 45.3%,
9.2%, for PCI 30.1%, 57.5%, 10.4%, and for no procedure
24.3%, 62.6%, and 7.5%. As expected, follow-up costs were
considerably impacted by whether or not revascularization was
performed. One-year revascularization rates were 15.0% for the
PCI group, 14.3% for no procedure, and only 2.2% for CABG.
One-year mean follow-up costs with and without revasculariza-
tion were: CABG ($28,867 with and $12,401 without revascu-
larization), PCI ($34,673 with and $8,344 without revascular-
ization), no procedure ($39,476 with and $14,020 without
revascularization). CONCLUSIONS: While hospitalization for
ACS with revascularization procedure was associated with
higher costs than hospitalization with no procedure, one-year
follow-up costs were higher in the no procedure group, largely
due to higher hospitalization costs.
PCV20
MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN
ACUTE DECOMPENSATED HEART FAILURE
Blackburn JC1, DiDomenico R1, Hilleman DE2, Schumock GT1,
Walton SM1
1University of Illinois at Chicago, Chicago, IL, USA, 2Creighton
University, Omaha, NE, USA
OBJECTIVES: Acute decompensated heart failure (ADHF) leads
to frequent hospital admissions and mortality; and represents a
signiﬁcant economic burden to patients, providers, and society.
Nesiritide may reduce downstream resource utilization and
improve patient outcomes when used early in the treatment.
METHODS: A Monte Carlo simulation for a hypothetical
cohort of 10,000 patients, based on a Markov model, was used
to estimate from the hospital perspective the expected values of
outcomes of interest. The model incorporates complications of
therapy (atrial ﬁbrillation and renal failure), location of inpatient
care (intensive care unit, inpatient ward, or emergency depart-
ment only), and hospital readmissions. Three stages of disease
were included within each cycle of the model: well (survive
ADHF hospitalization without suffering ADHF readmission),
sick (survive ADHF hospitalization but suffer ADHF readmis-
sion), and death. Transition probabilities were calculated from
prior published clinical trials. Hospital costs were obtained from
a pilot study conducted at Creighton University Medical Center.
The model was run over six cycles of one month each. RESULTS:
Based on the results of the Monte Carlo simulation, nesiritide
was dominant over standard therapy because it both reduces
costs and leads to a greater life expectancy. The average hospi-
tal costs per patient treated with nesiritide and standard therapy
were $9856 (SD ± $4676) and $10,953 (SD ± $5573) respec-
tively. Cost differences were mostly attributable to a lower prob-
ability of readmission for patients receiving nesiritide. The
percentage of patients who required 2 or more readmissions in
the nesiritide and in the standard therapy group were 25% and
31% respectively. Survival at six months also favored nesiritide.
CONCLUSIONS: Our model predicts that nesiritide, given
within 24 hours of hospitalization for ADHF, would lead to a
reduction in overall costs and the number of total readmissions,
and may decrease mortality over 6 months compared to stan-
dard therapy.
PCV21
COSTS OF DIAGNOSTIC PROCEDURES OF
INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY
MEXICAN INSTITUTE (IMSS)
Mould J1, Salinas-Escudero G1, Martinez-Valverde S2,
Garduño-Espinosa J1, Duran-Arenas L1
1Social Security Mexican Institute, Mexico City, Mexico, 2Social
Security Research Unit, Mexico City, Mexico
OBJECTIVES: An efﬁcient assignation of resources in the service
of hemodinamy requires the knowledge of costs of possible diag-
nostic procedure’s combinations. Currently, in Mexico the costs
for these procedures are very general and incomplete. The objec-
tive of this study was to estimate the direct and indirect medical
cost of different interventionist cardiology diagnostic procedures
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that are practiced in the hemodinamy service in the Cardiology
Hospital “Centro Nacional Siglo XXI” in Mexico City.
METHODS: Identiﬁcation of resource use at the hemodinamy
service was realized through expert opinion and the revision of
hospital records during the ﬁrst two months of 2005. Unitary
costs were obtained from the Accounting Department of the hos-
pital. The intervention’s cost estimation was realized with the
technique “case mix” and the perspective was that of the Social
Security Mexican Institute (IMSS). The direct medical costs
included: material of high specialty, medical instruments, drugs,
cineﬂuorscopy and human resources. Indirect medical costs
included: equipment, depreciation, laundry, electricity, tele-
phone, water, etc. Within the estimations of the interventions it
was included the use of counterpulsation balloon, cutting
balloon, glucoproteins (tiroﬁban or abciximab) and trombec-
tomy. RESULTS: Diagnostic catheterism was estimated in
US$328.7. The cost of the other interventions shifted in function
of the type of the stent used (conventional or medical). Inter-
vention of one vessel with conventional stent resulted in
US$1182.5; and with medical stent this raised to US$3438.5.
Also, intervention costs of one vessel trombectomy + counter-
pulsation balloon + glucoproteins inhibitors resulted in
U$7508.1. An intervention with two left vessel was calculated
in US$10,910.2 and with two left vessel and one right vessel, the
cost increased to US$13,706.7. CONCLUSIONS: Our study
results showed high direct medical costs heterogeneity on diag-
nostic procedures in a Mexican hemodinamy service. These
results are useful for cost containment policies and for further
health economics researches in Mexico.
PCV22
INPATIENT MANAGEMENT OF TRANSMURAL AND
SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION
(AMI): DIFFERENCES IN RESOURCE USE AND COST
O’Brien JA, Duran PA, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: To identify number of transmural and subendo-
cardial AMI cases, as well as related inpatient resource use and
cost by type of AMI. METHODS: Reported all-payer 2003 
hospital data from six states (CA, FL, MD, MA, TX, WA) were
analyzed. Transmural (410.00–410.60, 410.01–410.61) and
subendocardial (410.70, 410.71) AMI cases were identiﬁed using
ICD-9 principal diagnosis codes. AMI cases with other (410.80,
410.81) or unspeciﬁed (410.90, 410.91) codes were identiﬁed,
but excluded. Demographics, length of stay, admission source,
AMI location, secondary diagnosis and procedure codes, DRG
assignment, disposition status and reported charges were ana-
lyzed. Charges (accommodations, ancillary services) adjusted by
a 0.65 cost-to-charge ratio, and for medical inﬂation and geo-
graphic factors to reﬂect national values are reported as costs
(2005US$). RESULTS: Of the 168,831 AMI cases identiﬁed,
more than half (56%) were coded as subendocardial (n =
94,625). Transmural AMI was coded for 35% (n = 59,123); 9%
were coded as other or unspeciﬁed AMI. The subendocardial
AMI group had more females (47% vs. 40%), was older (mean
age: 72, median: 75 years vs. mean: 68, median: 70 years), and
had a slightly longer LOS (mean: 5.8, median: 4 days vs. mean:
5.5, median: 3.7 days), on average, than those with a transmural
AMI. Signiﬁcantly (p < 0.01) fewer patients with subendocardial
AMI had ICU days (50% vs. 75%), and percutaneous coronary
(47% vs. 27%) and stent (8% vs. 6%) procedures. Coronary-
bypass surgery rate was the same (10%) for both groups. Inpa-
tient case fatality rate was signiﬁcantly (p < 0.01) higher for
transmural group (10% vs. 7%). The average cost per stay for
transmural AMI was $34,012 (median: $23,880); $28,483
(median: $18,664) for subendocardial AMI. CONCLUSIONS:
Substantially fewer cases of acute transmural infarct were
reported in this dataset. Yet, when reported, they were 
more lethal, resource intensive and costly than a subendocardial
AMI.
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AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF
DEEP VEIN THROMBOSIS (DVT) IN BRAZIL
Fonseca M,Araujo G
Axia.Bio Consulting, São Paulo, Brazil
OBJECTIVE: DVT is an important problem in clinical practice.
This study aims to estimate the costs of treatment of DVT from
the perspective of the private medicine payers in Brazil.
METHODS: To determine actual costs of patient management
the resource use collected during comparative clinical trials often
is insufﬁcient. Although large data bases can be used to estimate
patient health care resource consumption they are not always
available. One reasonable data source is soliciting expert opinion
from clinicians. Two Delphi panels one for vascular surgeons,
and another for intensivists were performed in order to delineate
practice patterns and to obtain resource utilization for routine
treatment and monitoring, adverse event management and other
clinical parameters representative of community physicians man-
aging of DVT. Responses were obtained from seven vascular sur-
geons and ﬁve intensivists from various centers in Brazil with
experience of treating DVT. Percentage likelihood of complica-
tions due to thromboprophylaxis was determined based upon
physician consensus. A decision analytic model was designed to
project the costs associated with venous thromboembolism.
RESULTS: The detected mean cost (in Brazilian Reais) of DVT
was R$9895.23. The detected cost of diagnosing DVT was
R$74.01, the treatment cost without considering itxs complica-
tions was R$5208.76 and the complications cost, balanced by
incidence was R$4612.46. The cost to avoid a DVT by the use
of a thromboprophylaxis was R$177.68. CONCLUSIONS:
DVT costs are only a part of the costs incurred in treating high
risk surgical or clinical patients. These results clearly show the
substantial costs that a DVT may represent in the treatment 
of these patients that may be prevented by the use of 
thromboprophylaxis.
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AFRICAN AMERICANS’ RESPONSES TO DIRECT-TO-
CONSUMER ADVERTISING (DTCA) OF LIPITOR®
Yang Y1, Gourley D2, Gourley G2, Faris R3,Womeodu R2, Likens C2
1The University of Mississippi, University, MS, USA, 2The University of
Tennessee, Memphis,TN, USA, 3Methodist Hospital, Memphis,TN,
USA
OBJECTIVES: This study was designed to investigate how
African American patients respond to DTCA of prescription
drug Lipitor® and the relationships between potential inﬂuenc-
ing variables and patients’ responses. METHODS: Face-to-face
interview was employed for this study, and a convenience sample
consisting of 160 African American patients were interviewed at
a general medicine clinic in a public hospital. Short-Test of Func-
tional Health Literacy in Adults (S-TOFHLA) was administered
to all study participants. Then the participants were asked to
view a TV advertisement of Lipitor®, followed by DTCA-related
interviews. Patients’ demographic and socioeconomic informa-
tion was also collected during the interviews. Bivariate analyses
and logistic regressions were used to assess the relationships
between potential inﬂuencing variables and patients’ responses
